We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Show more
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (βTaihoβ) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.36 | -8.95325872284 | 15.19 | 15.47 | 13.61 | 549148 | 14.53637962 | CS |
4 | -1.44 | -9.43025540275 | 15.27 | 17.18 | 13.61 | 1001333 | 15.87905579 | CS |
12 | -2.73 | -16.4855072464 | 16.56 | 18.07 | 13.61 | 733709 | 15.89546423 | CS |
26 | -3.9 | -21.9966159052 | 17.73 | 20.31 | 13.61 | 789414 | 16.70159792 | CS |
52 | -8.07 | -36.8493150685 | 21.9 | 25.47 | 12.95 | 793563 | 17.52623032 | CS |
156 | -14.45 | -51.0961810467 | 28.28 | 49.1 | 12.95 | 855254 | 23.81708658 | CS |
260 | 5.23 | 60.8139534884 | 8.6 | 49.1 | 6.3 | 703217 | 24.06181161 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions